We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Catalyst Pharma Focuses on Firdapse Launch & Label Expansion
Read MoreHide Full Article
We issued an updated report on Catalyst Pharmaceuticals Inc. (CPRX - Free Report) on Jul 4.
In November 2018, the company’s Firdapse (amifampridine) tablets obtained FDA approval for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in adults. The drug became the first FDA-approved treatment for LEMS and also the first approved product in Catalyst’s portfolio.
The drug was launched in January 2019. In the first quarter of 2019, revenues came entirely from Firdapse. The initial uptake of the drug was encouraging. The company is optimistic about the drug and expects it to drive revenues in the upcoming quarters.
Catalyst Pharma’s shares have skyrocketed 111% year to date compared with the industry’s growth of 11.8%.
The company is also working on developing Firdapse for additional indications. It is currently conducting phase III studies on the drug for the treatment of congenital myasthenic syndromes (“CMS”) and anti-MuSK -antibody positive myasthenia gravis (MuSK-MG). The company expects to report top-line results from the phase III studies in the second half of 2019.
Catalyst is also conducting a proof-of-concept study, evaluating Firdapse as a symptomatic treatment for patients with SMA type III. The company expects to report top-line results from the study in the first half of 2020. A potential approval of the drug for additional indications will further drive sales for the company.
Apart from these, the company is in early stages of developing a longer-acting formulation of Firdapse to provide a better treatment alternative that will integrate well with patients' daily activities. It is working to develop a formulation that provides optimum level of efficacies through day and night. Hence, the formulation will be more convenient and patient-friendly.
However, all the other candidates in Catalyst’s portfolio are in early stages of development. Thus, the successful development and commercialization of drug candidates are highly crucial for the company.
Recently, Catalyst Pharmafiled a suit against the FDA and several related parties, challenging the recent approval of Jacobus Pharmaceutical Co's drug, Ruzurgi, for the treatment of LEMS in pediatric patients.
According to the lawsuit, the approval of Ruzurgi, in May 2019, violated provisions of the FDA regulations regarding labeling, resulting in misbranding in violation of the Federal Food, Drug, and Cosmetic Act (FDCA). The lawsuit also alleges that the approval also violated Catalyst's rights to exclusivity for its drug, Firdapse. Among other remedies, the suit seeks an order vacating the FDA's approval of Ruzurgi.
Some other top-ranked stocks in the biotech sector are Alnylam Pharmaceuticals Inc. (ALNY - Free Report) , Applied Genetics Technologies Corp. and Acorda Therapeutics Inc. . While Alnylam and Applied Genetics carry a Zacks Rank #1 (Strong Buy), Acorda carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Alnylam’s loss per share estimates have narrowed from $6.90 to $6.43 for 2020 in the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with average beat of 8.93%.
Applied Genetics’ loss per share estimates have narrowed from $2.39 to $2.15 for 2020 in the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with average beat of 83.47%.
Acorda’s loss per share estimates have narrowed from $3.16 to $3.09 for 2020 in the past 60 days. The company delivered a positive earnings surprise in the trailing four quarters, with average beat of 79.32%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Catalyst Pharma Focuses on Firdapse Launch & Label Expansion
We issued an updated report on Catalyst Pharmaceuticals Inc. (CPRX - Free Report) on Jul 4.
In November 2018, the company’s Firdapse (amifampridine) tablets obtained FDA approval for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in adults. The drug became the first FDA-approved treatment for LEMS and also the first approved product in Catalyst’s portfolio.
The drug was launched in January 2019. In the first quarter of 2019, revenues came entirely from Firdapse. The initial uptake of the drug was encouraging. The company is optimistic about the drug and expects it to drive revenues in the upcoming quarters.
Catalyst Pharma’s shares have skyrocketed 111% year to date compared with the industry’s growth of 11.8%.
The company is also working on developing Firdapse for additional indications. It is currently conducting phase III studies on the drug for the treatment of congenital myasthenic syndromes (“CMS”) and anti-MuSK -antibody positive myasthenia gravis (MuSK-MG). The company expects to report top-line results from the phase III studies in the second half of 2019.
Catalyst is also conducting a proof-of-concept study, evaluating Firdapse as a symptomatic treatment for patients with SMA type III. The company expects to report top-line results from the study in the first half of 2020. A potential approval of the drug for additional indications will further drive sales for the company.
Apart from these, the company is in early stages of developing a longer-acting formulation of Firdapse to provide a better treatment alternative that will integrate well with patients' daily activities. It is working to develop a formulation that provides optimum level of efficacies through day and night. Hence, the formulation will be more convenient and patient-friendly.
However, all the other candidates in Catalyst’s portfolio are in early stages of development. Thus, the successful development and commercialization of drug candidates are highly crucial for the company.
Recently, Catalyst Pharmafiled a suit against the FDA and several related parties, challenging the recent approval of Jacobus Pharmaceutical Co's drug, Ruzurgi, for the treatment of LEMS in pediatric patients.
According to the lawsuit, the approval of Ruzurgi, in May 2019, violated provisions of the FDA regulations regarding labeling, resulting in misbranding in violation of the Federal Food, Drug, and Cosmetic Act (FDCA). The lawsuit also alleges that the approval also violated Catalyst's rights to exclusivity for its drug, Firdapse. Among other remedies, the suit seeks an order vacating the FDA's approval of Ruzurgi.
Catalyst Pharmaceuticals, Inc. Price
Catalyst Pharmaceuticals, Inc. price | Catalyst Pharmaceuticals, Inc. Quote
Zacks Rank & Other Stocks to Consider
Catalyst currently has a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the biotech sector are Alnylam Pharmaceuticals Inc. (ALNY - Free Report) , Applied Genetics Technologies Corp. and Acorda Therapeutics Inc. . While Alnylam and Applied Genetics carry a Zacks Rank #1 (Strong Buy), Acorda carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Alnylam’s loss per share estimates have narrowed from $6.90 to $6.43 for 2020 in the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with average beat of 8.93%.
Applied Genetics’ loss per share estimates have narrowed from $2.39 to $2.15 for 2020 in the past 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with average beat of 83.47%.
Acorda’s loss per share estimates have narrowed from $3.16 to $3.09 for 2020 in the past 60 days. The company delivered a positive earnings surprise in the trailing four quarters, with average beat of 79.32%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases. Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>